Livingbridge has sold a minority stake in CREATE Fertility
CREATE Fertility is a national provider of fertility services in the UK and a pioneer in natural and mild IVF techniques, which are less drug intensive approaches to IVF. Its first IVF centre was opened in 2008 and operated for five years as a single site. In 2013, the decision was made to expand the business to make natural and mild IVF accessible nationally. Livingbridge was selected as a minority investor to help facilitate this expansion. The business now operates eight UK clinics, including innovative low-cost clinic ‘abc IVF’, which combined with their international operations, means CREATE now performs more than 4,000 treatments each year.
Lincoln acted as the exclusive financial adviser to Livingbridge.
Matthew Lee, Managing Director & UK Head of Healthcare at Lincoln International commented:
“We are delighted to have advised on this transaction, Lincoln’s 2nd in the IVF sector in the last few months. Having closely followed the expansion of CREATE over the past few years, we are pleased to have supported Livingbridge on their exit.”
Matthew and the Lincoln team really know the IVF sector well and were super responsive in delivering our exit, from establishing an equitable valuation through to deal completion. Our investment in CREATE has been an excellent one and we wish the team and business every success in the future.
Meet our Senior Team
View More Transactions
Lincoln International acted in a co-advisory role on the sale to Imperial Dade, a portfolio company of Audax
Lincoln International is pleased to announce that Wilson HEC, LLC has sold Hydra-Electric Company to Loar Group
Lincoln International is delighted to have been a financial advisor of SST Group on the sale of its residential business to Groupe Atlantic
Lincoln is pleased to announce that AIM Aerospace, a portfolio company of Liberty Hall Capital Partners, has executed a definitive agreement to be sold to Sekisui Chemical Group (TYO:4204) for $510 million in cash, subject to customary adjustments; the transaction is expected to close in the second half of 2019